Tools for Practice Outils pour la pratique


#66 Which is the best puffer for initial therapy in COPD?


CLINICAL QUESTION
QUESTION CLINIQUE
Which puffer has the greatest impact on clinical outcomes as the first-line long-acting inhaled treatment for COPD?


BOTTOM LINE
RÉSULTAT FINAL
Tiotropium (or other LAMA) +/- LABA is the best initial long-acting therapy for COPD, followed by a LABA (like salmeterol). Despite widespread use, inhaled steroids increase pneumonia risk and provide little if any benefit in COPD.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Long-acting antimuscarinic agents (LAMA) versus long-acting beta agonists (LABA) 
  • Cochrane review1 of seven Randomized Controlled Trials (RCTs) of 12,123 patients comparing tiotropium to LABA (formoterol, indacaterol, salmeterol) over 3-12 months. 
    • More patients exacerbation-free with tiotropium72.7% versus 70.5% with LABANumber Needed to Treat (NNT)=46. 
  • INVIGORATE:2 One year RCT (3,444 patients) randomized to tiotropium 18 mcg or indacaterol 150 mcg, each once daily. 
    • More patients exacerbation-free with tiotropium: 65% versus 60% with indacaterol, NNT=20. 
  • No difference in mortality or quality of life.1,2 
LAMA versus LABA plus steroid: 
  • INSPIRE:3 Two year trial (1,323 patients) comparing tiotropium 18 mcg daily to salmeterol/fluticasone 50/500 mcg BID. 
    • No difference in exacerbations, and no clinical difference in quality of life. 
    • While there were differences in some secondary outcomes, drop-out was high (39%) and no outcome data was collected on drop-outs. 
      • Cochrane reviewers4 felt the results were unreliable. 
LAMA + LABA versus LABA plus steroid: 
  • FLAME:5 One year RCT (3,362 patients) comparing indacaterol/glycopyrronium 110/50 mcg once daily versus salmeterol/fluticasone 50/500 mcg BID. 
    • LAMA/LABA versus LABA/steroid had lower: 
      • Exacerbation rate 0.88 (0.82-0.94). 
      • Risk of pneumonia: 3.2% versus 4.8%, NNT=63. 
    • No difference in mortality and no clinical difference in quality of life. 
  • Meta-analysis of eight trials (4,392 patients) showed similar results.6 
LABA versus steroid: 
  • Cochrane review7 (seven studies, 5,997 patients). 
    • No difference in exacerbations and no clinical difference in quality of life. 
    • Steroids caused more pneumonia, and possibly increased mortality (odds ratio 1.17, 95% CI 0.97-1.42).
Context:  
  • Most trials above were industry funded, generally favoring the sponsor’s drug. 
  • Inhaled steroids increase the risk of pneumonia8 [Number Needed to Harm (NNH)=44] and fractures9 (NNH=83).   
  • Guidelines,10 written before many of these trials were published, recommend tiotropium or LABA as initial therapy. 
updated July 26 2016 by Ricky


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • G. Michael Allan MD CCFP
  • James McCormack BSc(Pharm) PharmD

1. Chong J, Karner C, Poole P. Cochrane Database Syst Rev. 2012; 9:CD009157.

2. Decramer ML, Chapman KR, Dahl R, et al. Lancet Respir Med. 2013; 1:524-33.

3. Wedzicha JA, Calverley PM, Seemungal TA, et al. Am J Respir Crit Care Med. 2008; 177:19-26.

4. Welsh EJ, Cates CJ, Poole P. Cochrane Database Syst Rev. 2013; 5:CD007891.

5. Wedzicha JA, Banerji D, Chapman KR, et al. N Engl J Med. 2016; 374:2222-34.

6. Horita N, Miyazawa N, Tomaru K, et al. Respirology. 2015; 20:1153-9.

7. Spencer S, Karner C, Cates CJ, et al. Cochrane Database Syst Rev. 2011; 12:CD007033.

8. Festic E, Bansal V, Gupta E, et al. COPD. 2016; 13:312-26.

9. Loke YK, Cavallazzi R, Singh S. Thorax. 2011; 66:699-708.

10. Qaseem A, Wilt TJ, Weinberger SE, et al. Ann Intern Med. 2011; 155:179-91.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.